1/23
A comprehensive vocabulary review of cancer treatment modalities, chemotherapy classifications, radiation safety protocols, and oncologic nursing interventions.
Curative Therapy
A cancer treatment goal focused on completely eliminating or curing the disease.
Control Therapy
A treatment goal aimed at slowing disease growth, stopping the spread, and stabilizing the cancer.
Palliative Therapy
A treatment approach designed to relieve pain, physical symptoms, and stress to promote comfort rather than curing the disease.
Biotherapy
A cancer treatment modality that uses substances derived from living organisms to fight disease, regulate immune responses, or target specific cells.
Teletherapy
External beam radiation therapy where the radiation source is outside the body; utilizes tattoo markings for beam alignment, and neither the patient nor their body excreta is radioactive.
Brachytherapy
Internal radiation therapy delivered via sealed implanted radioactive seeds or unsealed radioactive isotopes administered into the body.
Sealed Radiation
A form of internal radiation therapy where the radioactive source is implanted very near or within the tumor, making the patient radioactive while the implant remains in place.
Unsealed Radiation
A form of internal radiation where the isotope is administered orally, intracavitary, or intravenously, causing both the patient and their bodily excreta to be radioactive.
Dosimeter Badge
A personal radiation monitoring device that healthcare workers must wear at all times to measure occupational radiation exposure when caring for patients undergoing implant radiation therapy.
Radiation Implant Safety Precautions
Safety parameters requiring healthcare staff and visitors to limit visits to under 21hr, stay at least 6ft away, avoid pregnant caregivers, and use long-handled forceps to handle dislodged radioactive elements into a lead container.
Total Body Surface Area (TBSA)
The clinical measurement index used to calculate and individualize dosage regimens for chemotherapy administration.
Alkylating Agents
Cell cycle non-specific chemotherapy agents (e.g., Cyclophosphamide, Cisplatin, Busulfan, Chlorambucil) that interfere with DNA synthesis and replication, known to cause general bone marrow suppression and specific bladder, kidney, and nerve damage.
Antimetabolites
Cell cycle specific chemotherapy medications active in the S phase (e.g., Methotrexate, 5FU, Cytarabine) that disrupt DNA and RNA synthesis in rapidly dividing cells.
Anti-Tumor Antibiotics
Cell cycle non-specific cytotoxic drugs (e.g., Doxorubicin, Bleomycin, Mitomycin) that bind cellular DNA and inhibit DNA and RNA synthesis by breaking the helix, carrying specific cardio, pulmonary, and hepatic toxicities.
Antimitotics
Cell cycle specific chemotherapy agents active in the M phase (e.g., Vincristine, Vinblastine, Paclitaxel) that frequently act as vesicants and carry high risks of hypersensitivity and neurotoxicity.
Topoisomerase 1 Inhibitors
Cell cycle specific chemotherapy agents active in the S phase (e.g., Irinotecan, Topotecan) that disrupt DNA topoisomerase enzymes that manage the winding, supercoiling, and tangling of DNA.
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A neurotoxic adverse effect of chemotherapy affecting 30%−40% of patients, characterized by numbness, tingling, stabbing pain, weakness, and loss of sensation in the extremities.
Stomatitis / Mucositis
Erythema, soreness, and ulceration of the oral mucosa caused by cancer therapy; managed with soft toothbrushes, avoidance of flossing, topical analgesics, water-based moisturizers, and avoidance of commercial mouthwashes.
Low Bacteria Diet
A dietary intervention for neutropenic oncology patients that strictly eliminates raw fruits, raw vegetables, and partially cooked meats to minimize infectious foodborne exposures.
Filgrastim (Neupogen)
A colony-stimulating factor prescribed to accelerate neutrophil recovery and increase white blood cell counts in neutropenic patients; commonly causes bone pain.
Erythropoietin (Epogen, Procrit)
A colony-stimulating factor that stimulates red blood cell production to treat therapy-related anemia in cancer patients.
Monoclonal Antibodies (MAB)
Targeted biologic response modifiers that attach to specific cellular markers, including Trastuzumab (Herceptin) for breast cancer, Rituximab (Rituxan) for non-Hodgkin's lymphoma, and Bevacizumab (Avastin) to inhibit tumor vascularization.
Sipuleucel-T (Provenge®)
An FDA-approved therapeutic cancer vaccine designed to induce an active cellular immune response for the treatment of prostate cancer.
Complementary & Alternative Medicine (CAM)
Non-conventional health practices and products not traditionally considered standard oncology care, utilized by 50% of cancer patients and representing over $34billion in annual spending.